{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:22:59Z","timestamp":1792480979159,"version":"4.5.0"},"posted":{"date-parts":[[2026,2,2]]},"group-title":"Pharmacology and Toxicology","reference-count":53,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Phase IIa pulmonary tuberculosis (TB) trials typically assess the early bactericidal activity (EBA) of monotherapy for over 14 days. However, few studies have evaluated drug combinations, even though optimal monotherapy doses may not directly translate to combinations. Translational pharmacokinetic-pharmacodynamic (PK-PD) modeling has shown promise in predicting human treatment responses based on preclinical monotherapy data; however, its application in drug combinations remains limited. This study aimed to extend and validate our previously developed translational monotherapy PK-PD modeling platform to predict the EBA of two-drug combinations. Interactions between bedaquiline, pretomanid, linezolid, and pyrazinamide were characterized using two modeling approaches: the empirical SUPER method and the mechanistic General Pharmacodynamic Interaction model. Both approaches were independently linked to our translational platform and validated using mouse data and Phase IIa clinical results from the NC-001 study. Both modeling methods identified consistent interaction patterns, including antagonistic interactions when bedaquiline was combined with either pretomanid or linezolid. Pyrazinamide has emerged as the most effective companion for both bedaquiline and pretomanid. Our platform reasonably predicted 14-day clinical sputum colony-forming unit counts for multiple two-drug combinations, with most observations falling within the 95% prediction intervals, supporting its use in accelerating regimen development. Our study demonstrated that the translational PK\u2013PD platform reliably predicts both short- and long-term outcomes for combinations, regardless of the interaction model. This supports its application across drug development stages to inform dose selection and effective companion drugs for anti-TB therapies.<\/jats:p>","DOI":"10.64898\/2026.01.29.702705","type":"posted-content","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:15:14Z","timestamp":1770066914000},"source":"Crossref","is-referenced-by-count":2,"title":["Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approach"],"prefix":"10.64898","author":[{"given":"Niurys","family":"de Castro Suarez","sequence":"first","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-9889","authenticated-orcid":false,"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-7287","authenticated-orcid":false,"given":"Jacqueline","family":"Ernest","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":false,"given":"Rada","family":"Savic","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026020511473964000_2026.01.29.702705v1.1","unstructured":"World Health Organization (WHO). 2025. Global tuberculosis report 2025. World Health Organization, Geneva. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/e97dd6f4-b567-4396-8680-717bac6869a9\/content."},{"key":"2026020511473964000_2026.01.29.702705v1.2","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"2026020511473964000_2026.01.29.702705v1.3","unstructured":"World Health Organization (WHO). 2022. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-susceptible tuberculosis treatment. World Health Organization, Geneva. https:\/\/www.who.int\/publications\/i\/item\/9789240048126."},{"key":"2026020511473964000_2026.01.29.702705v1.4","doi-asserted-by":"crossref","unstructured":"Nuermberger EL . 2017. Preclinical Efficacy Testing of New Drug Candidates. Microbiol Spectr 5.","DOI":"10.1128\/microbiolspec.TBTB2-0034-2017"},{"key":"2026020511473964000_2026.01.29.702705v1.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006421"},{"key":"2026020511473964000_2026.01.29.702705v1.6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.11.023","article-title":"Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations","volume":"24","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026020511473964000_2026.01.29.702705v1.7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bcp.14371","article-title":"Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis","volume":"87","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026020511473964000_2026.01.29.702705v1.8","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1814"},{"key":"2026020511473964000_2026.01.29.702705v1.9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-030920-011143"},{"key":"2026020511473964000_2026.01.29.702705v1.10","doi-asserted-by":"crossref","unstructured":"Ernest JP , Goh JJN , Strydom N , Wang Q , van Wijk RC , Zhang N , Deitchman A , Nuermberger E , Savic RM. 2023. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. Eur Respir J 62.","DOI":"10.1101\/2023.01.18.524608"},{"key":"2026020511473964000_2026.01.29.702705v1.11","doi-asserted-by":"crossref","first-page":"e0061524","DOI":"10.1128\/aac.00615-24","article-title":"Prospectively predicting BPaMZ phase IIb\/III trial outcomes using a translational mouse-to-human platform","volume":"68","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020511473964000_2026.01.29.702705v1.12","doi-asserted-by":"crossref","unstructured":"Li S-Y , Tasneen R , Tyagi S , Soni H , Converse PJ , Mdluli K , Nuermberger EL . 2017. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrob Agents Chemother 61.","DOI":"10.1128\/AAC.00913-17"},{"key":"2026020511473964000_2026.01.29.702705v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01929-y"},{"key":"2026020511473964000_2026.01.29.702705v1.14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/psp4.12226","article-title":"Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models","volume":"6","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026020511473964000_2026.01.29.702705v1.15","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1102"},{"key":"2026020511473964000_2026.01.29.702705v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"2026020511473964000_2026.01.29.702705v1.17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05293-11"},{"key":"2026020511473964000_2026.01.29.702705v1.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03822-14"},{"key":"2026020511473964000_2026.01.29.702705v1.19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01691-15"},{"key":"2026020511473964000_2026.01.29.702705v1.20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw467"},{"key":"2026020511473964000_2026.01.29.702705v1.21","doi-asserted-by":"crossref","unstructured":"Bigelow KM , Tasneen R , Chang YS , Dooley KE , Nuermberger EL . 2020. Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. Antimicrob Agents Chemother 64.","DOI":"10.1128\/AAC.01178-20"},{"key":"2026020511473964000_2026.01.29.702705v1.22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01010-23"},{"key":"2026020511473964000_2026.01.29.702705v1.23","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01010-23"},{"key":"2026020511473964000_2026.01.29.702705v1.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00898-06"},{"key":"2026020511473964000_2026.01.29.702705v1.25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB\/FeJ Mice","volume":"2","year":"2016","journal-title":"ACS Infect Dis"},{"key":"2026020511473964000_2026.01.29.702705v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2015.09.001"},{"key":"2026020511473964000_2026.01.29.702705v1.27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00720-11"},{"key":"2026020511473964000_2026.01.29.702705v1.28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/infdis\/jiab043","article-title":"Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model","volume":"224","year":"2021","journal-title":"J Infect Dis"},{"key":"2026020511473964000_2026.01.29.702705v1.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00217-12"},{"key":"2026020511473964000_2026.01.29.702705v1.30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01370-15"},{"key":"2026020511473964000_2026.01.29.702705v1.31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01354-09"},{"key":"2026020511473964000_2026.01.29.702705v1.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0141-z"},{"key":"2026020511473964000_2026.01.29.702705v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12147"},{"key":"2026020511473964000_2026.01.29.702705v1.34","doi-asserted-by":"crossref","unstructured":"Salinger DH , Subramoney V , Everitt D , Nedelman JR . 2019. Population Pharmacokinetics of the Antituberculosis Agent Pretomanid. Antimicrob Agents Chemother 63.","DOI":"10.1128\/AAC.00907-19"},{"key":"2026020511473964000_2026.01.29.702705v1.35","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis","volume":"74","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026020511473964000_2026.01.29.702705v1.36","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/psp4.12422","article-title":"NONMEM Tutorial Part II: Estimation Methods and Advanced Examples","volume":"8","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026020511473964000_2026.01.29.702705v1.37","first-page":"e38","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026020511473964000_2026.01.29.702705v1.38","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"2026020511473964000_2026.01.29.702705v1.39","unstructured":"Medscape. Drug interactions checker. Medscape. https:\/\/reference.medscape.com\/drug-interactionchecker. Retrieved 24 September 2024."},{"key":"2026020511473964000_2026.01.29.702705v1.40","doi-asserted-by":"crossref","unstructured":"Zhang N , Strydom N , Tyagi S , Soni H , Tasneen R , Nuermberger EL , Savic RM . 2020. Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies. Antimicrob Agents Chemother 64.","DOI":"10.1128\/AAC.01727-19"},{"key":"2026020511473964000_2026.01.29.702705v1.41","doi-asserted-by":"crossref","first-page":"e0156223","DOI":"10.1128\/aac.01562-23","article-title":"Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis","volume":"68","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020511473964000_2026.01.29.702705v1.42","doi-asserted-by":"crossref","unstructured":"Xu J , Li S-Y , Almeida DV , Tasneen R , Barnes-Boyle K , Converse PJ , Upton AM , Mdluli K , Fotouhi N , Nuermberger EL . 2019. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrob Agents Chemother 63.","DOI":"10.1128\/AAC.00021-19"},{"key":"2026020511473964000_2026.01.29.702705v1.43","doi-asserted-by":"crossref","first-page":"e0035724","DOI":"10.1128\/aac.00357-24","article-title":"Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis","volume":"68","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020511473964000_2026.01.29.702705v1.44","doi-asserted-by":"crossref","unstructured":"Xu J , Converse PJ , Upton AM , Mdluli K , Fotouhi N , Nuermberger EL . 2021. Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother 65.","DOI":"10.1128\/AAC.02418-20"},{"key":"2026020511473964000_2026.01.29.702705v1.45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2023.01.043","article-title":"Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents","volume":"186","year":"2023","journal-title":"Cell"},{"key":"2026020511473964000_2026.01.29.702705v1.46","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00035-23"},{"key":"2026020511473964000_2026.01.29.702705v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33736-5"},{"key":"2026020511473964000_2026.01.29.702705v1.48","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00686-08"},{"key":"2026020511473964000_2026.01.29.702705v1.49","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00074-08"},{"key":"2026020511473964000_2026.01.29.702705v1.50","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01303-12"},{"key":"2026020511473964000_2026.01.29.702705v1.51","unstructured":"Janssen Products, LP. 2024. SIRTURO\u00ae (bedaquiline) tablets, for oral use. Prescribing Information. Janssen Products, LP, Horsham, PA 19044, USA."},{"key":"2026020511473964000_2026.01.29.702705v1.52","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bmcl.2015.12.002","article-title":"Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids","volume":"26","author":"Rakesh","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"2026020511473964000_2026.01.29.702705v1.53","doi-asserted-by":"crossref","unstructured":"Alghamdi WA , Al-Shaer MH , Peloquin CA . 2018. Protein Binding of First-Line Antituberculosis Drugs. Antimicrob Agents Chemother 62.","DOI":"10.1128\/AAC.00641-18"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.01.29.702705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:47:51Z","timestamp":1770320871000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.01.29.702705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":53,"URL":"https:\/\/doi.org\/10.64898\/2026.01.29.702705","relation":{},"subject":[],"published":{"date-parts":[[2026,2,2]]},"subtype":"preprint"}}